CareDx (NASDAQ:CDNA – Get Free Report) was upgraded by investment analysts at Craig Hallum from a “hold” rating to a “buy” rating in a report released on Monday, Marketbeat reports. BTIG Research increased their target price on shares of CareDx from $28.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Weiss Ratings raised shares of CareDx from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday. Finally, Wall Street Zen upgraded CareDx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 3rd. CareDx Company Profile(Get Free Report)CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients.